:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Yuki Utakata, Takao Miwa, Shinji Unome, Naoya Masuda, Mikita Oi, Masashi Aiba, Kenji Imai, Koji Takai, Makoto Shiraki, Naoki Katsumura, Masahito Shimizu
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	https://onlinelibrary.wiley.com/doi/10.1111/apt.70592
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
by: Yuki Utakata, et al.
Published: (2026)

Letter: Disease Stage and Absolute Risk in Evaluating the Branched‐Chain Amino Acid to Tyrosine Ratio in Cirrhosis. Authors' Reply
by: Takao Miwa, et al.
Published: (2026)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
by: Zhanbo Qu
Published: (2026)

Usefulness of Retinol‐Binding Protein in Predicting Mortality in Patients With Chronic Liver Disease
by: Yuki Utakata, et al.
Published: (2025)

Response to “Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma”
by: Kenji Imai, et al.
Published: (2026)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
by: Mohamed El‐Kassas, et al.
Published: (2025)

Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma
by: Kenji Imai, et al.
Published: (2025)

Subcutaneous Adipose Tissue Accumulation is Associated With an Improved Prognosis in Patients With Hepatocellular Carcinoma
by: Kenji Imai, et al.
Published: (2026)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
by: Jiru Li, et al.
Published: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
by: J. M. Schattenberg, et al.
Published: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
by: Christian Labenz, et al.
Published: (2026)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
by: Bernardo de Faria Moraes, et al.
Published: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
by: Chachrit Khunsriraksakul, et al.
Published: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
by: David Tornai, et al.
Published: (2026)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
by: Deliang Huang, et al.
Published: (2026)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
by: Takao Miwa, et al.
Published: (2026)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
by: Lucie Simonis, et al.
Published: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
by: Mary Yue Wang, et al.
Published: (2026)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
by: Jeffrey D. McCurdy, et al.
Published: (2025)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
by: Mo‐Yao Tan, et al.
Published: (2024)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
by: Sai Kiran Kuchana, et al.
Published: (2026)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Soroor Owrangi, et al.
Published: (2024)

Animal Naming Test Can Identify Covert Hepatic Encephalopathy in Patients With Cirrhosis With Limited Influence From Age or Educational Level
by: Takao Miwa, et al.
Published: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
by: Christophe Corpechot
Published: (2026)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
by: Andrew W. Nguyen, et al.
Published: (2026)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
by: Abdulrahman Ismaiel
Published: (2026)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
by: Supachaya Sriphoosanaphan, et al.
Published: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
by: Bingqiong Wang, et al.
Published: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
by: Ting Wang, et al.
Published: (2024)

Editorial: Decoding Gut Failure in Cirrhosis—Villin‐1 and the Emergence of a Seventh Organ Failure. Authors' Reply
by: David Tornai, et al.
Published: (2026)

Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort
by: Scott Silvey, et al.
Published: (2025)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
by: Bernardo de Faria Moraes, et al.
Published: (2026)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
by: Shintaro Akiyama, et al.
Published: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
by: Virginia Solitano, et al.
Published: (2024)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
by: Irene Spinelli, et al.
Published: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
by: Nina Dominik, et al.
Published: (2024)